EP1729802A4 - Enhanced activity of hiv vaccine using a second generation immunomodulatory oligonucleotide - Google Patents

Enhanced activity of hiv vaccine using a second generation immunomodulatory oligonucleotide

Info

Publication number
EP1729802A4
EP1729802A4 EP05725427A EP05725427A EP1729802A4 EP 1729802 A4 EP1729802 A4 EP 1729802A4 EP 05725427 A EP05725427 A EP 05725427A EP 05725427 A EP05725427 A EP 05725427A EP 1729802 A4 EP1729802 A4 EP 1729802A4
Authority
EP
European Patent Office
Prior art keywords
enhanced activity
hiv vaccine
immunomodulatory oligonucleotide
generation
generation immunomodulatory
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP05725427A
Other languages
German (de)
French (fr)
Other versions
EP1729802A2 (en
Inventor
Mario Clerici
Richard Bartholomew
Dorothy Bray
Ekambar Kandimalla
Sudhir Agrawal
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immune Response Corp
Aceragen Inc
Original Assignee
Immune Response Corp
Hybridon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immune Response Corp, Hybridon Inc filed Critical Immune Response Corp
Publication of EP1729802A2 publication Critical patent/EP1729802A2/en
Publication of EP1729802A4 publication Critical patent/EP1729802A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • AIDS & HIV (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP05725427A 2004-03-12 2005-03-11 Enhanced activity of hiv vaccine using a second generation immunomodulatory oligonucleotide Withdrawn EP1729802A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US55287104P 2004-03-12 2004-03-12
PCT/US2005/008238 WO2005089231A2 (en) 2004-03-12 2005-03-11 Enhanced activity of hiv vaccine using a second generation immunomodulatory oligonucleotide

Publications (2)

Publication Number Publication Date
EP1729802A2 EP1729802A2 (en) 2006-12-13
EP1729802A4 true EP1729802A4 (en) 2009-12-16

Family

ID=34994209

Family Applications (1)

Application Number Title Priority Date Filing Date
EP05725427A Withdrawn EP1729802A4 (en) 2004-03-12 2005-03-11 Enhanced activity of hiv vaccine using a second generation immunomodulatory oligonucleotide

Country Status (7)

Country Link
US (1) US20050266015A1 (en)
EP (1) EP1729802A4 (en)
JP (1) JP2008500963A (en)
CN (1) CN101217973A (en)
AU (1) AU2005222909B2 (en)
CA (1) CA2557443A1 (en)
WO (1) WO2005089231A2 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US20030022854A1 (en) 1998-06-25 2003-01-30 Dow Steven W. Vaccines using nucleic acid-lipid complexes
AR040996A1 (en) 2002-08-19 2005-04-27 Coley Pharm Group Inc IMMUNE STIMULATING NUCLEIC ACIDS
PT2241325E (en) 2002-10-29 2012-04-12 Coley Pharm Gmbh Use of cpg oligonucleotides in the treatment of hepatitis c virus infection
MY159370A (en) 2004-10-20 2016-12-30 Coley Pharm Group Inc Semi-soft-class immunostimulatory oligonucleotides
US7470674B2 (en) * 2005-11-07 2008-12-30 Idera Pharmaceuticals, Inc. Immunostimulatory properties of oligonucleotide-based compounds comprising modified immunostimulatory dinucleotides
CN101517082B (en) 2006-09-27 2014-01-22 科勒制药有限责任公司 Cpg oligonucleotide analogs containing hydrophobic t analogs with enhanced immunostimulatory activity
DK2575878T3 (en) * 2010-05-28 2018-08-13 Zoetis Belgium S A VACCINES INCLUDING CHOLESTEROL AND CPG AS THE ONLY ADJUVENT CARRIER MOLECULES

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005021726A2 (en) * 2003-08-28 2005-03-10 The Immune Response Corporation Immunogenic hiv compositions and related methods

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5912332A (en) * 1996-07-26 1999-06-15 Hybridon, Inc. Affinity-based purification of oligonucleotides using soluble multimeric oligonucleotides
JP4726630B2 (en) * 2003-01-16 2011-07-20 イデラ ファーマシューティカルズ インコーポレイテッド Modulating the immunostimulatory properties of oligonucleotide-based compounds by using modified immunostimulatory dinucleotides

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005021726A2 (en) * 2003-08-28 2005-03-10 The Immune Response Corporation Immunogenic hiv compositions and related methods

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
"ADJUVANT LICENSED FOR THE DEVELOPMENT OF HIV VACCINE", AIDS VACCINE WEEK, 3 November 2003 (2003-11-03), pages 1 - 2, XP008114567 *
"IMMUNE RESPONSE LICENCES HYBRIDON'S AMPLIVAX VACCINE ADJUVANT", BIOTECH PATENT NEWS, October 2003 (2003-10-01), pages 1 - 3, XP008114568 *
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; February 2004 (2004-02-01), KANDIMALLA E R ET AL: "HYB 2055: A second-generation immunomodulatory oligonucleotide containing CpR motifs potently reverses allergic airway inflammation and airway hyperresponsiveness in mouse models of established asthma.", XP002554290, Database accession no. PREV200400210055 *
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; January 2001 (2001-01-01), MOSS RONALD B ET AL: "Human immunodeficiency virus (HIV)-specific immune responses are generated with the simultaneous vaccination of a gp120-depleted, whole-killed HIV-1 immunogen with cytosine-phosphorothioate-guanine dinucleotide immunostimulatory sequences of DNA", XP002554289, Database accession no. PREV200100103648 *
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, vol. 113, no. 2 Supplement, February 2004 (2004-02-01), 60TH ANNUAL MEETING OF THE AMERICAN ACADEMY OF ALLERGY, ASTHMA AND IMMUNOLOGY (AAAAI); SAN FRANCISCO, CA, USA; MARCH 19-23, 2004, pages S219, ISSN: 0091-6749 *
JOURNAL OF HUMAN VIROLOGY, vol. 4, no. 1, January 2001 (2001-01-01), pages 39 - 43, ISSN: 1090-9508 *
TRABATTONI D ET AL: "Immunization with gp120-depleted whole killed HIV immunogen and a second-generation CpG DNA elicits strong HIV-specific responses in mice", VACCINE, BUTTERWORTH SCIENTIFIC. GUILDFORD, GB, vol. 24, no. 9, 27 February 2006 (2006-02-27), pages 1470 - 1477, XP025151907, ISSN: 0264-410X, [retrieved on 20060227] *
TRABATTONI ET AL: "HIV-1 ANTIGEN IN ASSOCIATION WITH A SECOND-GENERATION IMMUNOMODULATORY OLIGONUCLEOTIDE, AMPLIVAX, ELICITS HIV-SPECIFIC IMMUNITY INDEPENDENTLY OF THE USE OF INCOMPLETE FREUND'S ADJUVANT", INT CONF AIDS, vol. 15, 11 July 2004 (2004-07-11) - 16 July 2004 (2004-07-16), pages 15, XP002554287, Retrieved from the Internet <URL:http://gateway.nlm.nih.gov/MeetingAbstracts/ma?f=102280770.html> [retrieved on 20091105] *
TRABATTONI ET AL: "HIV-1 IMMUNOGEN IN ASSOCIATION WITH AMPLIVAX, A SECOND-GENERATION IMMUNOMODULATORY OLIGONUCLEOTIDE, ELICITS HIV-SPECIFIC IMMUNITY", INT CONF AIDS, 11 July 2004 (2004-07-11) - 16 July 2004 (2004-07-16), pages 15, XP002554288, Retrieved from the Internet <URL:http://gateway.nlm.nih.gov/MeetingAbstracts/ma?f=102283616.html> [retrieved on 20091105] *

Also Published As

Publication number Publication date
AU2005222909A1 (en) 2005-09-29
WO2005089231A2 (en) 2005-09-29
WO2005089231A3 (en) 2007-12-06
EP1729802A2 (en) 2006-12-13
JP2008500963A (en) 2008-01-17
CA2557443A1 (en) 2005-09-29
CN101217973A (en) 2008-07-09
AU2005222909B2 (en) 2010-03-11
US20050266015A1 (en) 2005-12-01

Similar Documents

Publication Publication Date Title
EP1729802A4 (en) Enhanced activity of hiv vaccine using a second generation immunomodulatory oligonucleotide
EP1766096A4 (en) Siv and hiv vaccination using rhcmv- and hcmv-based vaccine vectors
HK1215052A1 (en) A nucleotide vaccine
TWI365064B (en) Oral care implement
TWI369974B (en) Oral care implement
HK1082392A1 (en) Oral care implement
HK1106987A1 (en) Oral care implement
TWI365191B (en) Vaccine
AU2003224725A8 (en) Hiv therapeutic
EP1682173A4 (en) Listeria-based epha2 vaccines
EP1603590A4 (en) Influenza virus vaccine
IL178971A0 (en) Vaccine for periodontal disease
GB0409940D0 (en) Vaccine
HK1214534A1 (en) Influenza vaccination
AU2003282498A8 (en) Hiv vaccine formulations
AU2003301850A8 (en) Hiv vaccine
EP1732580A4 (en) Epha2 vaccines
GB0411150D0 (en) Vaccine
ZA200709605B (en) HIV vaccine
GB0413510D0 (en) Vaccine
EP1884241A4 (en) A oral preparation comprising dyclonine hydrochloride
GB0412563D0 (en) Preparation of a catalyst
ZA200804099B (en) Multiclade HIV vaccines
GB0412407D0 (en) Vaccine
GB0428381D0 (en) Vaccine

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA HR LV MK YU

DAX Request for extension of the european patent (deleted)
PUAK Availability of information related to the publication of the international search report

Free format text: ORIGINAL CODE: 0009015

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 39/00 20060101AFI20080104BHEP

17P Request for examination filed

Effective date: 20080204

RBV Designated contracting states (corrected)

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU MC NL PL PT RO SE SI SK TR

RAX Requested extension states of the european patent have changed

Extension state: YU

Payment date: 20080204

Extension state: MK

Payment date: 20080204

Extension state: LV

Payment date: 20080204

Extension state: HR

Payment date: 20080204

Extension state: BA

Payment date: 20080204

Extension state: AL

Payment date: 20080204

A4 Supplementary search report drawn up and despatched

Effective date: 20091118

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 39/21 20060101ALI20091110BHEP

Ipc: A61K 39/00 20060101AFI20080104BHEP

17Q First examination report despatched

Effective date: 20100615

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20101026